Zurück
| Semester | Frühjahrsemester 2013 |
| Angebotsmuster | Jedes Frühjahrsem. |
| Dozierende |
Patrick Yves Müller (y.mueller@unibas.ch)
Alex Odermatt (alex.odermatt@unibas.ch, BeurteilerIn) |
| Inhalt | The objective of this new lecture series is to cover safety assessment and ADMET strategies required to advance low molecular weight drug candidates and therapeutic monoclonal antibodies "from bench to bedside". The focus is on toxicology/safety/ADMET approaches leading to first human entry (clinical phase I) including selection of the first human dose. State of the art drug development strategies aiming at clinical entry are exemplified by representatives from the pharmaceutical industry and from academia by including interactive case studies. Week 1: Safety assessment: introduction to early drug development (A. Hartmann, P.Y. Müller) Target selectivity and drug candidate selectivity; Anti-Target screening (A. Odermatt) Week 2: DMPK & ADME assessment (M. Gassen); Toxicity / safety Biomarkers (F. Dieterle); Safety pharmacology (E. Kuntz); Week 3: Safety assessment: MedChem parameters, formulations & CYP inhibition; On-Target toxicity - off-target safety profiling; In vivo toxicology; Qualification of preclinical safety findings (P.Y. Müller) Week 4: Safety endpoints in later development; Safety considerations for biotechnology-derived pharmaceuticals; Dose selections for first-human entry: general concepts, NMEs (P.Y. Müller) Week 5: Special considerations for biotechnology-derived pharmaceuticals (T. Singer); Dose selections for first human entry: mAbs, MABEL (P. Epsie, P.Y. Müller); Immunogenicity of biologics (H. Kropshofer); Regulatory considerations for first-in-human trials (Q. Desvigne); Week 6: Exam |
| Lernziele | - to know the toxicological and safety pharmacological ADME studies and end points and to understand the reasons why they are necessary in order to test a drug for the first time in human - to know differences between low molecular weight drugs and therapeutic antibodies with respect to preclinical toxicology and early clinical development - to know the relevance and methods in the assessment of drug selectivity - to understand qualitative and quantitative estimates of toxicological parameters with respect to first in human dose - to understand the principles of design and safety/toxicity end points of phase I studies |
| Unterrichtssprache | Englisch |
| Einsatz digitaler Medien | kein spezifischer Einsatz |
| HörerInnen willkommen |
| Intervall | Wochentag | Zeit | Raum |
|---|
Keine Einzeltermine verfügbar, bitte informieren Sie sich direkt bei den Dozierenden.
| Module |
Modul Specific Knowledge in Toxicology (Master Toxikologie) (Pflicht) Vertiefungsmodul Pharmakologie (Master Pharmazeutische Wissenschaften) Vertiefungsmodul Toxikologie (Master Pharmazeutische Wissenschaften) |
| Leistungsüberprüfung | Lehrveranst.-begleitend |
| Hinweise zur Leistungsüberprüfung | Friday 12.04.2013, 08.15 - 10.00, Room Grosser Hörsaal HS1, Pharmazentrum |
| An-/Abmeldung zur Leistungsüberprüfung | Anmelden: Belegen; Abmelden: Dozierende |
| Wiederholungsprüfung | keine Wiederholungsprüfung |
| Skala | 1-6 0,5 |
| Wiederholtes Belegen | beliebig wiederholbar |
| Zuständige Fakultät | Philosophisch-Naturwissenschaftliche Fakultät, studiendekanat-philnat@unibas.ch |
| Anbietende Organisationseinheit | Departement Pharmazeutische Wissenschaften |